Hospital-based surveillance of respiratory syncytial virus in Central Queensland
DOI:
https://doi.org/10.33321/cdi.2025.49.041Keywords:
respiratory syncytial virus, RSV, RSV hospitalisation, paediatric respiratory infections, acute lower respiratory tract infections, epidemiology, RSV testing, respiratory illness, AustraliaAbstract
Background
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections, especially in infants and young children globally. Despite its impact, RSV testing and epidemiological data remain limited, particularly in regional Australia. Central Queensland, with its subtropical climate, provides a unique setting in which to study RSV trends, testing patterns, and associated hospital burden.
Methods
This study used hospital-based data to analyse RSV-related hospitalisations and testing from Central Queensland. Data were collected retrospectively between 2018 and 2021 and prospectively between 2022 and 2023. Eligible cases included individuals presenting to or admitted at any hospitals in Central Queensland with laboratory-confirmed RSV or RSV-related diagnoses based on ICD-10-AM codes. The analysis focused on RSV-related hospital admissions and hospitalisation outcomes. Incidence rate ratios (IRR) for hospitalisation rates between the two periods were calculated.
Results
Between 2018 and 2023, there were 1,279 RSV-related hospitalisations, with 53.2% of cases being male. Infants under 12 months accounted for the highest proportion of admissions (38.4%). RSV-related hospitalisations peaked during the prospective study period, rising from 123 in 2018 to 357 in 2023. The hospitalisation rate among infants was significantly higher in the prospective study period compared to the retrospective study period (IRR: 2.2; 95% confidence interval [95% CI]: 1.8–2.6; p < 0.001). The Indigenous population had a significantly higher hospitalisation rate than the non-Indigenous population over the whole study period (IRR: 3.1; 95% CI: 2.7–3.6; p < 0.001). The median length of stay was two days, with 20.6% of those hospitalised requiring ventilation, 2.2% needing intensive care unit (ICU) support, and 0.9% of hospitalisations resulting in death. Mortality was highest among those aged 60 years and above (91.7%). Although infants under 12 months had the lowest RSV testing rates (9.8%), they had the highest test positivity rate (16.4%).
Conclusions
RSV admissions have been under-reported due to limited testing. Increased awareness and widespread testing during prospective surveillance revealed a significant rise in RSV-related admissions. These findings underscore the need for enhanced RSV testing, improved resource allocation, and expanded immunisation efforts to effectively manage the burden of RSV.
Downloads
References
Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58. doi: https://doi.org/10.1016/S0140-6736(17)30938-8.
McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(7):ofac300. doi: https://doi.org/10.1093/ofid/ofac300.
Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23–24 March 2015. Vaccine. 2016;34(2):190–7. doi: https://doi.org/10.1016/j.vaccine.2015.05.093.
Self A, Van Buskirk J, Clark J, Cochrane JE, Knibbs L, Cass-Verco J et al. Respiratory syncytial virus disease morbidity in Australian infants aged 0 to 6 months: a systematic review with narrative synthesis. BMC Public Health. 2023;23(1):2560. doi: https://doi.org/10.1186/s12889-023-17474-x.
Gebremedhin AT, Hogan AB, Blyth CC, Glass K, Moore HC. Developing a prediction model to estimate the true burden of respiratory syncytial virus (RSV) in hospitalised children in Western Australia. Sci Rep. 2022;12(1):332. doi: https://doi.org/10.1038/s41598-021-04080-3.
Saravanos GL, Sheel M, Homaira N, Dey A, Brown E, Wang H et al. Respiratory syncytial virus-associated hospitalisations in Australia, 2006–2015. Med J Aust. 2019;210(10):447–53. doi: https://doi.org/10.5694/mja2.50159.
Makari D, Staat MA, Henrickson KJ, Wu X, Ambrose CS. The underrecognized burden of respiratory syncytial virus among infants presenting to US emergency departments. Clin Pediatr (Phila). 2015;54(6):594–7. doi: https://doi.org/10.1177/0009922814546040.
Rozenbaum MH, Judy J, Tran D, Yacisin K, Kurosky SK, Begier E. Low levels of RSV testing among adults hospitalized for lower respiratory tract infection in the United States. Infect Dis Ther. 2023;12(2):677–85. doi: https://doi.org/10.1007/s40121-023-00758-5.
Egeskov-Cavling AM, Johannesen CK, Lindegaard B, Fischer TK, PROMISE Investigators. Underreporting and misclassification of respiratory syncytial virus–coded hospitalization among adults in Denmark between 2015–2016 and 2017–2018. J Infect Dis. 2023;229(Supplement_1):S78–83. doi: https://doi.org/10.1093/infdis/jiad415.
Gale E, Smoll N, Al Imam MH, Walker J, Kirk M, Pam S et al. Epidemiology of respiratory syncytial virus in Central Queensland, Australia. Commun Dis Intell (2018). 2024;48. doi: https://doi.org/10.33321/cdi.2024.48.45.
Queensland Government Department of Environment and Science. Climate change in the Central Queensland region, version 1. Brisbane: Queensland Government; 2019. Available from: https://www.qld.gov.au/__data/assets/pdf_file/0020/68141/central-qld-climate-change-impact-summary.pdf.
Queensland Government Statistician’s Office. Queensland Regional Profiles. [Webpage.] Brisbane: Queensland Government Treasury; 2024. Available from: https://statistics.qgso.qld.gov.au/qld-regional-profiles.
Queensland Government Department of Health (Queensland Health). About us: Learn about our role in delivering world class health care to people in Central Queensland. [Webpage.] Brisbane: Queensland Health; May 2024. Available from: https://www.cq.health.qld.gov.au/about-us.
Queensland Government Statistician’s Office. InfoBank – Demography. [Webpage.] Brisbane: Queensland Government; 2024. Available from: https://qheps.health.qld.gov.au/hsu/infobank/infobank-demography#estimated.
Fitzpatrick T, Buchan SA, Mahant S, Fu L, Kwong JC, Stukel TA et al. Pediatric respiratory syncytial virus hospitalizations, 2017–2023. JAMA Netw Open. 2024;7(6):e2416077. doi: https://doi.org/10.1001/jamanetworkopen.2024.16077.
Britton PN, Hu N, Saravanos G, Shrapnel J, Davis J, Snelling T et al. COVID-19 public health measures and respiratory syncytial virus. Lancet Child Adolesc Health. 2020;4(11):e42–3. doi: https://doi.org/10.1016/S2352-4642(20)30307-2.
Openshaw PJM, Chiu C, Culley FJ, Johansson C. Protective and harmful immunity to RSV infection. Annu Rev Immunol. 2017;35:501–32. doi: https://doi.org/10.1146/annurev-immunol-051116-052206.
Doty B, Ghaswalla P, Bohn RL, Stoszek SK, Panozzo CA. Incidence of RSV in adults: a comprehensive review of observational studies and critical gaps in information. J Infect Dis. 2024:jiae314. doi: https://doi.org/10.1093/infdis/jiae314.
Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodríguez-Tenreiro C, Sly P, Ramilo O et al. Respiratory syncytial virus seasonality: a global overview. J Infect Dis. 2018;217(9):1356–64. doi: https://doi.org/10.1093/infdis/jiy056.
Broberg EK, Waris M, Johansen K, Snacken R, Penttinen P, European Influenza Surveillance Network. Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016. Euro Surveill. 2018;23(5):17-00284. doi: https://doi.org/10.2807/1560-7917.ES.2018.23.5.17-00284.
Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther. 2009;14(2):75–85. doi: https://doi.org/10.5863/1551-6776-14.2.75.
Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–55. doi: https://doi.org/10.1016/S0140-6736(10)60206-1.
Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465–77. doi: https://doi.org/10.1056/NEJMoa2213836.
Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425–35. doi: https://doi.org/10.1056/NEJMoa2309189.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
